Poor clinical outcome of relapsed/refractory diffuse large B-cell                    lymphoma with MYC translocation treated with polatuzumab vedotin, bendamustine,                    and rituximab

Masuho Saburi; Masanori Sakata; Yousuke Kodama; Keiichi Uraisami; Hiroyuki Takata; Yasuhiko Miyazaki; Junpei Wada; Shogo Urabe; Eiichi Ohtsuka

doi:10.3960/jslrt.23017

Short Communication

Poor clinical outcome of relapsed/refractory diffuse large B-cell lymphoma with MYC translocation treated with polatuzumab vedotin, bendamustine, and rituximab

Masuho Saburi , Masanori Sakata, Yousuke Kodama, Keiichi Uraisami, Hiroyuki Takata, Yasuhiko Miyazaki, Junpei Wada, Shogo Urabe, Eiichi Ohtsuka

著者情報

Masuho Saburi 責任著者
Department of Hematology, Oita Prefectural Hospital, Oita, Japan,
Masanori Sakata
Department of Hematology, Oita Prefectural Hospital, Oita, Japan,
Yousuke Kodama
Department of Hematology, Oita Prefectural Hospital, Oita, Japan,
Keiichi Uraisami
Department of Hematology, Oita Prefectural Hospital, Oita, Japan,
Hiroyuki Takata
Department of Hematology, Oita Prefectural Hospital, Oita, Japan,
Yasuhiko Miyazaki
Department of Hematology, Oita Prefectural Hospital, Oita, Japan,
Junpei Wada
Department of Pathology, Oita Prefectural Hospital, Oita, Japan
Shogo Urabe
Department of Pathology, Oita Prefectural Hospital, Oita, Japan
Eiichi Ohtsuka
Department of Hematology, Oita Prefectural Hospital, Oita, Japan,

キーワード: diffuse large B-cell lymphoma, polatuzumab vedotin, bendamustine, MYC translocation

ジャーナルオープンアクセス

2023 年 63 巻 3 号 p. 201-204

DOI https://doi.org/10.3960/jslrt.23017

Browse “Advance online publication” version

詳細

責任著者(Corresponding author)

J-STAGEへの登録はこちら（無料）